| Zhang, Hao |
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction |
|
|
| Recruiting | 4 | 970 | RoW | Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin | Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd. | Branch Atheromatous Disease | 06/24 | 09/24 | | |
NCT06597201: Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition. |
|
|
| Recruiting | 4 | 400 | RoW | amino acid (15) peritoneal dialysis solution, glucose peritoneal dialysis solution | Chengdu Qingshan Likang Pharmaceutical Co., Ltd | End Stage Renal Disease (ESRD) | 06/25 | 06/25 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer |
|
|
| Recruiting | 3 | 480 | US | Glufosfamide, Fluorouracil, 5-FU | Eleison Pharmaceuticals LLC. | Metastatic Pancreatic Adenocarcinoma | 06/26 | 12/26 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT04476485: Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy |
|
|
| Recruiting | N/A | 1000 | RoW | endocrine therapy | Shengjing Hospital | Breast Cancer | 12/21 | 12/26 | | |
NCT05296369: Folic Acid Interferes With Radiation Esophagitis |
|
|
| Recruiting | N/A | 90 | RoW | Folic acid | Guizhou Medical University | Lung Cancer | 05/23 | 05/23 | | |
| Recruiting | N/A | 620 | RoW | Lobectomy-First, Lymphadenectomy-First | Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, RenJi Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Jinan University, The First Affiliated Hospital with Nanjing Medical University, Hebei Medical University Fourth Hospital, Shanghai Changzheng Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Suining Central Hospital, Ningbo Medical Center Lihuili Hospital, Shanxi Provincial Cancer Hospital, The Affiliated Hospital of Xuzhou Medical University, The General Hospital of Eastern Theater Command, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Kunming Medical University, Fujian Provincial Hospital, Tianjin Chest Hospital, Sichuan Cancer Hospital and Research Institute, Shenzhen People's Hospital, Tang-Du Hospital, Shandong Provincial Hospital, Gansu Provincial Hospital, Wuhan Union Hospital, China, Wuhan TongJi Hospital, The Affiliated Hospital of Qingdao University, West China Hospital, The First Affiliated Hospital of Nanchang University, Jiangsu Cancer Institute & Hospital, Dongguan People's Hospital, First People's Hospital of Foshan | Non Small Cell Lung Cancer | 12/24 | 12/29 | | |
NCT05042531: Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia |
|
|
| Recruiting | N/A | 30 | RoW | Azacitidine, Dasatinib | LanZhou University, Beijing Health Alliance Charitable Foundation | Acute Myeloid Leukemia | 09/23 | 12/23 | | |
NCT05735262: pBFS Guided Precision Neuromodulation Treatment for ASD |
|
|
| Recruiting | N/A | 100 | RoW | active iTBS, sham iTBS | Changping Laboratory, China Rehabilitation Research Center | Autism Spectrum Disorder | 03/24 | 01/25 | | |
NCT05842304: Individualized Precision rTMS for Language Recovery in Patients After Ischemic Stroke: a Multi-center RCT |
|
|
| Recruiting | N/A | 180 | RoW | active cTBS, sham cTBS | Changping Laboratory | Stroke, Ischemic, Aphasia | 05/25 | 05/26 | | |
NCT05475756: Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis |
|
|
| Recruiting | N/A | 264 | RoW | Intrauterine Biological Barrier, Intrauterine Adhesion Barrier Gel | Beijing Tiantan Hospital, Zhangzhou Municipal Hospital of Fujian Province, Guangzhou First People's Hospital, Tang-Du Hospital, Suzhou Municipal Hospital, Anhui Provincial Hospital | Intrauterine Adhesion | 05/24 | 05/25 | | |
NCT06499974: POASAC Study (Preoperative Anemia Severity and Classification Study) |
|
|
| Recruiting | N/A | 1000 | RoW | | Peking Union Medical College Hospital | Anemia | 12/25 | 12/26 | | |
NCT05890846: Precision TMS Treatment Guided by Personalized Brain Functional Sectors (pBFS) for ASD |
|
|
| Recruiting | N/A | 66 | RoW | active iTBS, sham iTBS, traditional 1on1 course | Changping Laboratory, Henan Provincial People's Hospital, China Rehabilitation Research Center | Autism Spectrum Disorder | 09/24 | 09/25 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
| Not yet recruiting | N/A | 800 | NA | | HBI Solutions Inc., Shanghai Children's Medical Center, mProbe Inc. | Kawasaki Disease | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 648 | RoW | Posterior Pericardiotomy | Changhai Hospital | Atrial Fibrillation (AF), Cardiac Events | 12/25 | 06/26 | | |
| Recruiting | N/A | 15 | RoW | Pomalidomide, Pomalyst | LanZhou University, Beijing Health Alliance Charitable Foundation | Multiple Myeloma | 05/25 | 05/25 | | |
NCT05953415: pBFS-guided iTBS Over the Left DLPFC for Chronic PSCI |
|
|
| Recruiting | N/A | 60 | RoW | active iTBS, sham iTBS | Changping Laboratory, China Rehabilitation Research Center | Chronic Stroke, Cognitive Impairment | 07/25 | 10/25 | | |
| Xu, Gang |
NCT06528015: Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy |
|
|
| Not yet recruiting | 4 | 206 | RoW | probiotics combined with enteric-coated budesonide capsule, probiotics placebo combined with enteric-coated budesonide capsules | Gang Xu, China Primary Health Care Foundation | Glomerulonephritis, IGA, Probiotics, Budesonide | 12/26 | 12/28 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT05512988: Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 ) |
|
|
| Recruiting | 1/2 | 44 | RoW | UC-MSC, Saline solution | Tongji Hospital, Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd. | Chronic Kidney Diseases | 04/24 | 05/24 | | |
| Recruiting | N/A | 80 | RoW | Fluroquinolones, levoflocaxin (Cravit), moxifloxacin (Avelox), ciprofloxacin (Cifran), Beta-lactamase inhibitor, amoxicillin clavulanate potassium compound (Junerqing) | Guangzhou Institute of Respiratory Disease | Bronchiectasis | 12/23 | 12/23 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Riella, Miguel Carlos |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
| Recruiting | 3 | 2750 | Europe, Canada, RoW | Spironolactone 25Mg Tablet, Placebo Oral Tablet | Population Health Research Institute, Canadian Institutes of Health Research (CIHR) | Endstage Renal Disease | 07/25 | 04/26 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Araújo, Maria das Graças |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Oliveira, Rodrigo Correa |
| Terminated | 2 | 19 | Europe, US, RoW | Daxdilimab, Placebo (Normal Saline) | Amgen, Horizon Therapeutics Ireland DAC | Lupus Nephritis | 01/24 | 01/24 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
BEOD, NCT05859022: Metabolic Effects of Bariatric Arterial Embolization vs Bariatric Surgery |
|
|
| Recruiting | N/A | 30 | Europe | Roux-en-Y gastric By-pass (RYGB) surgery, Bariatric Arterial Embolization (BAE) procedure | Universidade Nova de Lisboa, cruz vermelha hospital | Obesity, Type2diabetes, Bariatric Surgery Candidate, Metabolic Disease | 08/25 | 10/25 | | |
| Santos, Daniel Ceballos |
| Recruiting | 3 | 914 | Canada, RoW | Novaferon, Standard of Care, Placebo | Genova Inc. | Covid19 | 08/22 | 08/22 | | |
| Completed | 3 | 200 | US | Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo | Cristcot LLC, Cristcot HCA LLC | Ulcerative Proctitis | 07/24 | 09/24 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Bacci, Marcelo R |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) |
|
|
| Recruiting | 3 | 320 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes | 09/26 | 10/26 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
| Recruiting | 3 | 2750 | Europe, Canada, RoW | Spironolactone 25Mg Tablet, Placebo Oral Tablet | Population Health Research Institute, Canadian Institutes of Health Research (CIHR) | Endstage Renal Disease | 07/25 | 04/26 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT04801017: A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects |
|
|
| Not yet recruiting | 2 | 18 | RoW | OT-101, Trabedersen, Artemisinin, ArtiVeda, Placebo, Normal saline | Oncotelic Inc. | COVID-19 | 08/21 | 10/21 | | |
| Terminated | 2 | 19 | Europe, US, RoW | Daxdilimab, Placebo (Normal Saline) | Amgen, Horizon Therapeutics Ireland DAC | Lupus Nephritis | 01/24 | 01/24 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Huang, Anbin |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Murali, Karumathil |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| ARROYO, ALEJANDRO JESUS |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Terminated | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
| Terminated | 2 | 19 | Europe, US, RoW | Daxdilimab, Placebo (Normal Saline) | Amgen, Horizon Therapeutics Ireland DAC | Lupus Nephritis | 01/24 | 01/24 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| MacKinnon, Bruce |
| Recruiting | 2 | 100 | US, RoW | ANG-3070, Placebo | Angion Biomedica Corp, Angion Biomedica Corp. | Glomerular Disease, Proteinuria | 07/23 | 08/23 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| TANG, Xun |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Recruiting | N/A | 22032 | RoW | Frequent and automatic cardiovascular risk assessment, Dynamic risk monitoring, Regular GP visits | Peking University, Yinzhou District Center for Disease Control and Prevention | Cardiovascular Diseases | 07/28 | 07/28 | | |
| Laranjinha, Ivo |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Kent, Joanna |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Siqueira, Thayse Mayara Aragão |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Siliano, Juliana Mansur |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
